BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38079020)

  • 21. Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes.
    Zhang Y; Lucas CG; Young JS; Morshed RA; McCoy L; Oberheim Bush NA; Taylor JW; Daras M; Butowski NA; Villanueva-Meyer JE; Cha S; Wrensch M; Wiencke JK; Lee JC; Pekmezci M; Phillips JJ; Perry A; Bollen AW; Aghi MK; Theodosopoulos P; Chang EF; Hervey-Jumper SL; Berger MS; Clarke JL; Chang SM; Molinaro AM; Solomon DA
    Neuro Oncol; 2022 Oct; 24(10):1749-1762. PubMed ID: 35395677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
    Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A
    Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
    Funakoshi Y; Hata N; Takigawa K; Arita H; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Sako A; Umehara T; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iwaki T; Mizoguchi M
    Cancer Med; 2021 May; 10(10):3177-3187. PubMed ID: 33838014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
    Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
    Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
    Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
    Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
    Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insular primary glioblastomas with IDH mutations: Clinical and biological specificities.
    Hata N; Hatae R; Yoshimoto K; Murata H; Kuga D; Akagi Y; Sangatsuda Y; Suzuki SO; Iwaki T; Mizoguchi M; Iihara K
    Neuropathology; 2017 Jun; 37(3):200-206. PubMed ID: 28116838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarker-driven diagnosis of diffuse gliomas.
    Appin CL; Brat DJ
    Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.
    Hasselblatt M; Jaber M; Reuss D; Grauer O; Bibo A; Terwey S; Schick U; Ebel H; Niederstadt T; Stummer W; von Deimling A; Paulus W
    J Neuropathol Exp Neurol; 2018 Jun; 77(6):422-425. PubMed ID: 29444314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline.
    Velázquez Vega JE; Brat DJ; Ryken TC; Olson JJ
    J Neurooncol; 2020 Nov; 150(2):143-164. PubMed ID: 33215342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glioblastomas harboring gene fusions detected by next-generation sequencing.
    Woo HY; Na K; Yoo J; Chang JH; Park YN; Shim HS; Kim SH
    Brain Tumor Pathol; 2020 Oct; 37(4):136-144. PubMed ID: 32761533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1.
    Suwala AK; Stichel D; Schrimpf D; Maas SLN; Sill M; Dohmen H; Banan R; Reinhardt A; Sievers P; Hinz F; Blattner-Johnson M; Hartmann C; Schweizer L; Boldt HB; Kristensen BW; Schittenhelm J; Wood MD; Chotard G; Bjergvig R; Das A; Tabori U; Hasselblatt M; Korshunov A; Abdullaev Z; Quezado M; Aldape K; Harter PN; Snuderl M; Hench J; Frank S; Acker T; Brandner S; Winkler F; Wesseling P; Pfister SM; Reuss DE; Wick W; von Deimling A; Jones DTW; Sahm F
    Acta Neuropathol; 2021 Jul; 142(1):179-189. PubMed ID: 33876327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.
    Vaubel RA; Tian S; Remonde D; Schroeder MA; Mladek AC; Kitange GJ; Caron A; Kollmeyer TM; Grove R; Peng S; Carlson BL; Ma DJ; Sarkar G; Evers L; Decker PA; Yan H; Dhruv HD; Berens ME; Wang Q; Marin BM; Klee EW; Califano A; LaChance DH; Eckel-Passow JE; Verhaak RG; Sulman EP; Burns TC; Meyer FB; O'Neill BP; Tran NL; Giannini C; Jenkins RB; Parney IF; Sarkaria JN
    Clin Cancer Res; 2020 Mar; 26(5):1094-1104. PubMed ID: 31852831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Characterization of "True" Low-Grade IDH-Wildtype Astrocytomas.
    Richardson TE; Hatanpaa KJ; Walker JM
    J Neuropathol Exp Neurol; 2021 Apr; 80(5):431-435. PubMed ID: 33829259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
    Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
    Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
    Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
    J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?
    Weller M; Reifenberger G
    Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.